Sohini Das

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

Molbio Diagnostics plans to expand its overseas business through subsidiary OptraScan after the latter secured USFDA clearance, while diversifying beyond tuberculosis-focused public-health revenues.

Audi expects sales to remain broadly flat in 2026 before returning to growth in 2027 as the new models begin contributing

Anand Mahindra says old career templates no longer hold as jobs appear and disappear rapidly

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

The company expects exports to contribute 35 per cent of FY27 revenue as demand improves in North America and Europe, helping absorb newly created manufacturing capacity

Revenue rises 77% YoY; PBIT margin improves 860 bps as XEV 9S drives volumes, EV penetration

Auto and farm profits rise 18%; services PAT jumps 80% on improved performance at MMFSL and Tech Mahindra

Rs 322-crore funding led by Lightrock values Mahindra Last Mile Mobility at Rs 10,822 crore as the company targets a second-half FY27 listing

Company scouts for USFDA-approved assets; on track for ₹1,000 crore in revenue by FY28

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Dahej facility to begin commercial production in FY28; company targets nutraceuticals, functional foods and import substitution

Tyre maker expects premium products, exports and Camso integration to support growth, while higher raw-material costs, freight and geopolitical risks weigh on margins

Thailand has become the second country after the US to approve Dr Reddy's first-in-class antibiotic zoliflodacin, a milestone that could accelerate access to the drug across emerging markets

Maruti, VinFast and Tesla capture 8.1% market, account for 18% of incremental registrations

SUV contribution to Maruti Suzuki's domestic sales has risen from 12 per cent in FY23 to around 30 per cent in the first quarter of FY27

MD & CEO Dilip Jose says the hospital chain will use the ₹8,000-crore fresh issue largely to repay debt, while pursuing organic expansion and selective acquisitions in key markets

The refreshed Brezza will target first-time, replacement and additional-car buyers as Maruti responds to changing preferences and intensifying competition in compact SUVs

The auto components maker aims to replicate the ten-fold growth achieved over the past decade, backed by robotics, physical AI, acquisitions and new mobility technologies